text: Window of opportunity  CAMBRIDGE -- Three-year-old Momenta Pharmaceuticals Inc. already has seen its share of milestones. Its scientists cloned the first Heparin sugar-degrading enzyme, a breakthrough in understanding the role of complex sugars as a conduit for viruses and diseases. Its executives recruited medical luminaries like M. Judah Folkman and Eugene Braunwald to the company's scientific advisory board.